CA3126334A1 - Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity - Google Patents

Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity Download PDF

Info

Publication number
CA3126334A1
CA3126334A1 CA3126334A CA3126334A CA3126334A1 CA 3126334 A1 CA3126334 A1 CA 3126334A1 CA 3126334 A CA3126334 A CA 3126334A CA 3126334 A CA3126334 A CA 3126334A CA 3126334 A1 CA3126334 A1 CA 3126334A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
aromatic
compound
substituent group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3126334A
Other languages
English (en)
French (fr)
Inventor
Yusuke TATENO
Manabu Katou
Toshihiro Wada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CA3126334A1 publication Critical patent/CA3126334A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3126334A 2019-01-11 2020-01-10 Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity Pending CA3126334A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-003073 2019-01-11
JP2019003073 2019-01-11
PCT/JP2020/000553 WO2020145369A1 (ja) 2019-01-11 2020-01-10 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体

Publications (1)

Publication Number Publication Date
CA3126334A1 true CA3126334A1 (en) 2020-07-16

Family

ID=71520981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3126334A Pending CA3126334A1 (en) 2019-01-11 2020-01-10 Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Country Status (11)

Country Link
US (1) US12227509B2 (https=)
EP (1) EP3909583A4 (https=)
JP (1) JP7608166B2 (https=)
KR (1) KR20210114001A (https=)
CN (2) CN119409703A (https=)
AU (1) AU2020207716A1 (https=)
BR (1) BR112021012428A2 (https=)
CA (1) CA3126334A1 (https=)
MX (1) MX2021008050A (https=)
TW (1) TWI840489B (https=)
WO (1) WO2020145369A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022016394A (ja) * 2020-07-10 2022-01-21 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体を含有する医薬組成物
WO2023038039A1 (ja) 2021-09-08 2023-03-16 塩野義製薬株式会社 抗肥満作用の関与する疾患の予防及び治療用医薬
WO2026008045A1 (zh) * 2024-07-04 2026-01-08 苏州信诺维医药科技股份有限公司 一种含有炔基的螺环化合物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8232282B2 (en) 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
AU2007342368A1 (en) 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US20110275647A1 (en) 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
KR20100097077A (ko) 2009-02-25 2010-09-02 주식회사 중외제약 Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
JP5853033B2 (ja) 2011-03-01 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体
WO2012124744A1 (ja) 2011-03-14 2012-09-20 大正製薬株式会社 含窒素縮合複素環化合物
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
CN103012397B (zh) 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
JP2014009165A (ja) 2012-06-27 2014-01-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン化合物
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
WO2014133134A1 (ja) 2013-02-28 2014-09-04 味の素株式会社 新規テトラヒドロピリドピリミジノン誘導体
CA2907532A1 (en) 2013-03-25 2014-10-02 Sanofi Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)
CN104109160B (zh) 2013-04-17 2017-12-15 上海翰森生物医药科技有限公司 吡咯并n杂环类化合物及其制备方法和医药用途
SG11201509070YA (en) 2013-05-29 2015-12-30 Bristol Myers Squibb Co Dihydropyridinone mgat2 inhibitors
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
EP3097095A1 (en) 2014-01-24 2016-11-30 AbbVie Inc. Furo-3-carboxamide derivatives and methods of use
JP6513075B2 (ja) 2014-02-27 2019-05-15 国立大学法人 東京大学 オートタキシン阻害活性を有する縮合ピラゾール誘導体
JP2017078024A (ja) 2014-02-28 2017-04-27 味の素株式会社 新規テトラヒドロピリドピリミジノン誘導体
SMT201900256T1 (it) 2014-03-07 2019-07-11 Bristol Myers Squibb Co Inibitori dell'mgat2 diidropiridinonici sostituiti con tetrazolone
SG11201607392SA (en) 2014-03-07 2016-10-28 Bristol Myers Squibb Co Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
EP3129376B1 (en) 2014-03-27 2018-12-26 Janssen Pharmaceutica NV Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors
WO2015191681A2 (en) 2014-06-11 2015-12-17 Bristol-Myers Squibb Company Substituted pyridinones as mgat2 inhibitors
JP2017171579A (ja) * 2014-08-11 2017-09-28 味の素株式会社 新規テトラヒドロピリドピリミジノン誘導体
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016106009A1 (en) 2014-12-22 2016-06-30 Eli Lilly And Company Erk inhibitors
JP2018052818A (ja) * 2015-01-28 2018-04-05 武田薬品工業株式会社 スルホンアミド化合物
JP2016164154A (ja) 2015-02-26 2016-09-08 塩野義製薬株式会社 オートタキシン阻害活性を有する７位無置換縮合ピラゾール誘導体
WO2017069224A1 (ja) 2015-10-22 2017-04-27 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するスピロ環誘導体
US10335401B2 (en) * 2015-12-21 2019-07-02 Shionogi & Co., Ltd. Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
JP6665575B2 (ja) 2016-02-23 2020-03-13 ブラザー工業株式会社 プログラム
JP2020158390A (ja) * 2017-06-20 2020-10-01 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物

Also Published As

Publication number Publication date
US20220135577A1 (en) 2022-05-05
TWI840489B (zh) 2024-05-01
JP7608166B2 (ja) 2025-01-06
EP3909583A1 (en) 2021-11-17
BR112021012428A2 (pt) 2021-09-08
KR20210114001A (ko) 2021-09-17
TW202043235A (zh) 2020-12-01
WO2020145369A1 (ja) 2020-07-16
MX2021008050A (es) 2021-08-05
CN119409703A (zh) 2025-02-11
EP3909583A4 (en) 2022-08-17
AU2020207716A1 (en) 2021-07-15
JPWO2020145369A1 (ja) 2021-11-25
US12227509B2 (en) 2025-02-18
CN113557021A (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
JP7493635B2 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
CA3101950A1 (en) Polycyclic pyridone derivative
JP7068743B2 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
US20260098031A1 (en) Monocyclic compound having glp-1 receptor agonist activity
CA3126334A1 (en) Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity
US10335401B2 (en) Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
JP2022016394A (ja) Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体を含有する医薬組成物
RU2803743C2 (ru) Производное дигидропиразолопиразинона, обладающее ингибирующей активностью в отношении mgat-2
JP2026046943A (ja) Ｍｇａｔ２阻害活性を有するジヒドロピリドピラジノン誘導体
AU2019211806A1 (en) Condensed cyclic compound having dopamine D3 receptor antagonism
HK40059861A (en) Fused ring derivative having mgat-2 inhibitory activity
WO2025026882A1 (en) Novel compounds
HK40043566A (en) Polycyclic pyridone derivative
HK1231058A1 (en) 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103